Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

CLS Q1’22: Our Comments

2022-05-19

11:00

EN

GM

Erik Nordström

Gustaf Meyer

Redeye provides its comments on CLS’ Q1’22 report. With ongoing discussions with potential new commercial partners in the urology segment, three new clinical studies initiated as well as a pending 510(k) approval for the second generation of TRANBERG Thermal Therapy System with Thermoguide Workstation, the company has an interesting period ahead.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers